Literature DB >> 3732085

Branhamella catarrhalis as an indirect pathogen.

J K Wardle.   

Abstract

In 7 patients with bronchopulmonary infections, treatment with penicillin antibiotics failed to eradicate Haemophilus influenzae or Streptococcus pneumoniae which were sensitive to the antibiotic used. The sputum of these patients contained both the pathogen and beta-lactamase-producing Branhamella catarrhalis. No antibacterial activity was detectable in sputum samples obtained from patients receiving a penicillin antibiotic. This suggests that B. catarrhalis can act as an indirect pathogen, protecting accompanying pathogens from antibiotics by producing an antibiotic-destroying enzyme.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732085     DOI: 10.2165/00003495-198600313-00020

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  3 in total

1.  "Indirect pathogenicity" of penicillinase-producing enterobacteria in chronic bronchial infections.

Authors:  J L Maddocks; J R May
Journal:  Lancet       Date:  1969-04-19       Impact factor: 79.321

2.  Bronchopulmonary infection due to Branhamella catarrhalis: 11 cases assessed by transtracheal puncture.

Authors:  G Ninane; J Joly; M Kraytman
Journal:  Br Med J       Date:  1978-02-04

3.  Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections.

Authors:  N J Slevin; J Aitken; P E Thornley
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

  3 in total
  17 in total

Review 1.  Clinical use of cefuroxime in paediatric community-acquired pneumonia.

Authors:  C Olivier
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

2.  Interaction of Streptococcus pneumoniae and Moraxella catarrhalis: investigation of the indirect pathogenic role of beta-lactamase-producing moraxellae by use of a continuous-culture biofilm system.

Authors:  R K Budhani; J K Struthers
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

3.  Evaluation of a rapid method for identifying Branhamella catarrhalis.

Authors:  J Richards
Journal:  J Clin Pathol       Date:  1988-04       Impact factor: 3.411

4.  Detection of beta lactamase in sputum.

Authors:  C Connell; S Aspinall; J Corkill
Journal:  J Clin Pathol       Date:  1994-08       Impact factor: 3.411

5.  Moraxella (Branhamella) catarrhalis BRO beta-lactamase: a lipoprotein of gram-positive origin?

Authors:  H J Bootsma; P C Aerts; G Posthuma; T Harmsen; J Verhoef; H van Dijk; F R Mooi
Journal:  J Bacteriol       Date:  1999-08       Impact factor: 3.490

6.  Comparative analysis and supragenome modeling of twelve Moraxella catarrhalis clinical isolates.

Authors:  Jeremiah J Davie; Josh Earl; Stefan P W de Vries; Azad Ahmed; Fen Z Hu; Hester J Bootsma; Kim Stol; Peter W M Hermans; Robert M Wadowsky; Garth D Ehrlich; John P Hays; Anthony A Campagnari
Journal:  BMC Genomics       Date:  2011-01-26       Impact factor: 3.969

Review 7.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

8.  Molecular characterization of the BRO beta-lactamase of Moraxella (Branhamella) catarrhalis.

Authors:  H J Bootsma; H van Dijk; J Verhoef; A Fleer; F R Mooi
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Indirect pathogenicity of Haemophilus influenzae and Moraxella catarrhalis in polymicrobial otitis media occurs via interspecies quorum signaling.

Authors:  Chelsie E Armbruster; Wenzhou Hong; Bing Pang; Kristin E D Weimer; Richard A Juneau; James Turner; W Edward Swords
Journal:  MBio       Date:  2010-07-06       Impact factor: 7.867

10.  Bronchopulmonary infection due to B. catarrhalis. Clinical features and therapeutic response.

Authors:  D T McLeod; F Ahmad; M J Croughan; M A Calder
Journal:  Drugs       Date:  1986       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.